Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Current Liabilities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Total Current Liabilities for 11 consecutive years, with $103.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 6.29% to $103.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103.9 million through Dec 2025, down 6.29% year-over-year, with the annual reading at $103.9 million for FY2025, 6.29% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $103.9 million at Intellia Therapeutics, up from $93.7 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $131.1 million in Q3 2022, with the low at $60.7 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $105.1 million, with a median of $104.5 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities surged 107.75% in 2022, then fell 29.88% in 2023.
  • Over 5 years, Total Current Liabilities stood at $125.8 million in 2021, then rose by 0.57% to $126.6 million in 2022, then fell by 8.97% to $115.2 million in 2023, then decreased by 3.78% to $110.9 million in 2024, then fell by 6.29% to $103.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $103.9 million, $93.7 million, and $95.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.